Key result
Hypertension and diabetes share common pathophysiologic pathways, and optimization of lifestyle along with appropriate antihypertensive therapy remains the cornerstone in preventing cardiovascular disease.
Why the study?
Does antihypertensive therapy reduce cardiovascular disease events in patients with diabetes and hypertension?
Does antihypertensive therapy reduce cardiovascular disease events in patients with diabetes and hypertension?
Hypertension and diabetes are intertwined metabolic conditions that synergistically increase cardiovascular risk, highlighting the importance of lifestyle and pharmacological interventions.
Answers are grounded in this paper and cite their sources.
Reinforces lifestyle and antihypertensive optimization in comorbid patients; leaves open targeted interventions for shared pathways.
Hypertension (HTN) is an important risk factor for cardiovascular disease and its many manifestations. It shares pathogenic pathways with diabetes and is part of a common metabolic entity, the metabolic syndrome. When combined with diabetes, HTN has been shown to predict and promote increased risk for cardiovascular disease events over and above each risk factor alone. Of the components of this metabolic syndrome, HTN is relatively easy to diagnose and thereby more accessible for implementing preventive and treatment strategies. The recent release of Joint National Committee-8 guidelines for the treatment of HTN has fueled a debate on treatment target goals.
No takes yet. Share an insight, caveat, or question.
Sunkara et al. (2017) conducted a review in Hypertension and Diabetes. Antihypertensive therapy and lifestyle modifications was evaluated. Hypertension and diabetes share common pathophysiologic pathways, and optimization of lifestyle along with appropriate antihypertensive therapy remains the cornerstone in preventing cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: